News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
Expands clinical development of Oral KORSUVA™ into neuropathic pruritus STAMFORD, Conn. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by
View HTML
Toggle Summary Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD, Conn. , Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
View HTML
Toggle Summary Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
- Topline data expected in first half of 2021   - STAMFORD, Conn. , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting
View HTML
Toggle Summary Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
STAMFORD, Conn. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2020 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
STAMFORD, Conn. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020
- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented – - NDA submission for KORSUVA Injection   on track for fourth quarter 2020 - STAMFORD, Conn. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:
View HTML
Toggle Summary Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
Vifor Pharma secures commercial rights for IV Korsuva   in non- Fresenius Medical Care   dialysis clinics   representing approx. 66% of the market ,   under a profit - sharing arrangement   with Cara Cara will receive a USD 100 million upfront payment and an equity investment of USD 50 million IV
View HTML
Toggle Summary Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
STAMFORD, Conn. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML